Treatment in CML
Stand firm against progression
A novel treatment of cancer of the white blood cells:
Newly approved tyrosine kinase inhibitor (TKI) used in the treatment of adult patients with chronic phase (CP), accelerated phase (AP), or blast phase (BP) Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy. Please find detailed information on drug profile of this third-generation tyrosine kinase inhibitor (TKI) and the Mode of Action. Further latest study results, therapy management and dosing for the new drug are presented.